Document Detail

Relationship of serum dehydroepiandrosterone (DHEA), DHEA sulfate, and 5-androstene-3 beta, 17 beta-diol to risk of breast cancer in postmenopausal women.
MedLine Citation:
PMID:  9138660     Owner:  NLM     Status:  MEDLINE    
Laboratory evidence suggests a role for dehydroepiandrosterone (DHEA) and its metabolite 5-androstene-3 beta, 17 beta-diol (ADIOL) in mammary tumor growth. Serum DHEA also has been related to breast cancer in postmenopausal women, but the relationship of ADIOL to risk has not been evaluated previously. To assess the relationship of serum DHEA, its sulfate (DHEAS), and ADIOL with breast cancer risk in postmenopausal women, we conducted a prospective nested case-control study using serum from the Columbia, MO Breast Cancer Serum Bank. Cases included 71 healthy postmenopausal volunteers not taking replacement estrogens when they donated blood and who were diagnosed with breast cancer up to 10 years later (median, 2.9 years). Two randomly selected controls, who also were postmenopausal and not taking estrogens, were matched to each case on exact age, date (+/-1 year), and time (+/-2 h) of blood collection. Significant (trend P = 0.02) gradients of increasing risk of breast cancer were observed for increasing concentrations of DHEA and ADIOL, and women whose serum levels of these hormones were in the highest quartiles were at a significantly elevated risk compared to those in the lowest; their risk ratios were 4.0 [95% confidence interval (CI), 1.3-11.8) and 3.0 (95% CI, 1.0-8.6), respectively. The relationship of DHEAS to breast cancer was less consistent, but women whose serum DHEAS concentration was in the highest quartile also exhibited a significantly elevated risk ratio of 2.8 (95% CI, 1.1-7.4). Results of this prospective study support a role for the adrenal androgens, DHEA, DHEAS, and ADIOL, in the etiology of breast cancer.
J F Dorgan; F Z Stanczyk; C Longcope; H E Stephenson; L Chang; R Miller; C Franz; R T Falk; L Kahle
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology     Volume:  6     ISSN:  1055-9965     ISO Abbreviation:  Cancer Epidemiol. Biomarkers Prev.     Publication Date:  1997 Mar 
Date Detail:
Created Date:  1997-05-08     Completed Date:  1997-05-08     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9200608     Medline TA:  Cancer Epidemiol Biomarkers Prev     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  177-81     Citation Subset:  IM    
Division of Cancer Prevention and Control, National Cancer Institute, NIH, Bethesda, Maryland 20892-7326, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anabolic Agents / blood*
Androstenediol / blood*
Bias (Epidemiology)
Blood Donors
Breast Neoplasms / epidemiology*
Case-Control Studies
Confidence Intervals
Dehydroepiandrosterone / blood*
Dehydroepiandrosterone Sulfate / blood*
Follow-Up Studies
Linear Models
Middle Aged
Missouri / epidemiology
Odds Ratio
Postmenopause* / blood
Prospective Studies
Risk Factors
Reg. No./Substance:
0/Anabolic Agents; 521-17-5/Androstenediol; 53-43-0/Dehydroepiandrosterone; 651-48-9/Dehydroepiandrosterone Sulfate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  p53 alterations but no human papillomavirus infection in preinvasive and advanced squamous esophagea...
Next Document:  Evidence for at least two distinct groups of humoral immune reactions to papillomavirus antigens in ...